CA
HRTX icon

Continuum Advisory’s Heron Therapeutics HRTX Stock Holding History

Continuum Advisory’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-509
Closed -$631 – 1910
2024
Q3 		$631 Sell
509
-12
-2% -$29 ﹤0.01% 1733
2024
Q2 		$1.82K Sell
521
-61
-10% -$187 ﹤0.01% 1324
2024
Q1 		$1.71K Buy
+582
New +$1.46K ﹤0.01% 1341

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Continuum Advisory's HRTX Position: Q4 2024 in Review

Continuum Advisory sold out of Heron Therapeutics (HRTX) in Q4 2024, closing a stake of 509 shares — an estimated $631 sold.

Continuum Advisory first reported a position in HRTX in Q1 2024 and held it in 3 quarters. The position peaked at $1.82K in Q2 2024. 161 funds tracked by Wall St. Rank hold HRTX as of Q4 2024.

  • Continuum Advisory reported no remaining Heron Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Continuum Advisory sold 509 Heron Therapeutics shares in Q4 2024, an estimated $631.
  • Continuum Advisory first reported a position in Heron Therapeutics in Q1 2024 and held it in 3 quarters.
  • Continuum Advisory's Heron Therapeutics position peaked at $1.82K in Q2 2024.
  • 161 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2024.

Based on Continuum Advisory's 13F filing for Q4 2024, filed 18 Feb 2025.